INTRODUCTION: The aim of a double-blind study was to assess the efficacy of bright light therapy and/or imipramine in the treatment of inpatients suffering with recurrent non-seasonal major depressive disorder. METHOD: 34 in-patients with DSM-III-R diagnosis of major depressive disorder, recurrent type, were randomly allocated into 3 treatment groups. After 4-day washout period with baseline assessment they underwent 3 weeks of different types of treatment: a) Group A: bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day. b) Group B: bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo. c) Group C: dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day. Outcome measures included weekly Hamilton Psychiatric Rating Scale for Depression, Clinical Global Impression Scale, Montgomery and Asberg Psychiatric Rating Scale for Depression and Beck Depression Inventory. RESULTS: Patients of all three groups improved significantly. The improvement of the patients of group B treated with bright light therapy plus placebo was superior to the other two groups, but not significantly. CONCLUSION:Bright light therapy can be effective in the treatment of non-seasonal major depressive disorder.
RCT Entities:
INTRODUCTION: The aim of a double-blind study was to assess the efficacy of bright light therapy and/or imipramine in the treatment of inpatients suffering with recurrent non-seasonal major depressive disorder. METHOD: 34 in-patients with DSM-III-R diagnosis of major depressive disorder, recurrent type, were randomly allocated into 3 treatment groups. After 4-day washout period with baseline assessment they underwent 3 weeks of different types of treatment: a) Group A: bright light therapy (5000 lux from 6-8 a.m.) and imipramine 150 mg/day. b) Group B: bright light therapy (5000 lux from 6-8 a.m.) and imipramine-like placebo. c) Group C: dim red light (500 lux from 6-8 a.m.) and imipramine 150 mg/day. Outcome measures included weekly Hamilton Psychiatric Rating Scale for Depression, Clinical Global Impression Scale, Montgomery and Asberg Psychiatric Rating Scale for Depression and Beck Depression Inventory. RESULTS:Patients of all three groups improved significantly. The improvement of the patients of group B treated with bright light therapy plus placebo was superior to the other two groups, but not significantly. CONCLUSION: Bright light therapy can be effective in the treatment of non-seasonal major depressive disorder.
Authors: Lianqi Liu; Matthew R Marler; Barbara A Parker; Vicky Jones; Sherella Johnson; Mairav Cohen-Zion; Lavinia Fiorentino; Georgia Robins Sadler; Sonia Ancoli-Israel Journal: Support Care Cancer Date: 2005-04-29 Impact factor: 3.603
Authors: Davide Elia Bertani; Antonella Maria Pia De Novellis; Riccardo Farina; Emanuela Latella; Matteo Meloni; Carmela Scala; Laura Valeo; Gian Maria Galeazzi; Silvia Ferrari Journal: Int J Environ Res Public Health Date: 2021-02-09 Impact factor: 3.390
Authors: Stefan Perera; Rebecca Eisen; Meha Bhatt; Neera Bhatnagar; Russell de Souza; Lehana Thabane; Zainab Samaan Journal: BJPsych Open Date: 2016-03-04
Authors: I-Peng Chen; Chun-Chao Huang; Hui-Chun Huang; Fan-Pei Gloria Yang; Kai-Ting Ko; Yun-Tse Lee; Fang-Ju Sun; Shen-Ing Liu Journal: Int J Environ Res Public Health Date: 2022-09-29 Impact factor: 4.614
Authors: Eve Cosker; Marie Moulard; Samuel Schmitt; Karine Angioi-Duprez; Cédric Baumann; Vincent Laprévote; Raymund Schwan; Thomas Schwitzer Journal: BMJ Open Date: 2021-07-09 Impact factor: 2.692